Wim M. Mulleners

Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial

Wim M. Mulleners, Byung‐Kun Kim, Miguel J. A. Láinez et al. · The Lancet Neurology · 2020 · 283 citations

Pharmacy, Pharmacology, Pharmacotherapy +10

Visual Cortex Excitability in Migraine With and Without Aura

Wim M. Mulleners, Edward P. Chronicle, Joanne Palmer et al. · Headache The Journal of Head and Face Pain · 2001 · 196 citations

Life Sciences, Neurology, Neuroscience +16

Environmental exposure to pesticides and the risk of Parkinson's disease in the Netherlands

Maartje Brouwer, Anke Huss, Marianne van der Mark et al. · Environment International · 2017 · 167 citations · Full text

Pharmacy, Environmental Sciences, Toxicology +12

Integrated multidisciplinary care in Parkinson's disease: a non-randomised, controlled trial (IMPACT)

Marjolein A. van der Marck, Marten Munneke, Wim M. Mulleners et al. · The Lancet Neurology · 2013 · 126 citations

Nursing, Neurology, Clinical Neuroscience +8

Suppression of perception in migraine

Wim M. Mulleners, Edward P. Chronicle, J. E. Palmer et al. · Neurology · 2001 · 122 citations

Life Sciences, Neurology, Neuroscience +15